Clinical trial

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

NCT00806572

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2002-05-01

PhasePHASE2

Study timeline

Study start (unknown)2002-05-01Date precision: month

Registry last updated2017-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 1unresolved

Interventions

hOKT3gamma1(Ala-Ala)DRUG

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Immune Tolerance Network (ITN)collaborator

Mapped research locations

New YorkNew York, United States1 San FranciscoCalifornia, United States1 SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00806572 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.